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Abstract
Background: Phosphodiesterase 4 (PDE4) inhibitors increase intracellular cyclic adenosine monophosphate (cAMP),
leading to regulation of inflammatory cell functions. Roflumilast is a potent and targeted PDE4 inhibitor. The
objective of this study was to evaluate the effects of roflumilast on bronchoconstriction, airway
hyperresponsiveness (AHR), and airway inflammation in mild asthmatic patients undergoing allergen inhalation
challenge.
Methods: 25 subjects with mild allergic asthma were randomized to oral roflumilast 500 mcg or placebo, once
daily for 14 days in a double-blind, placebo-controlled, crossover study. Allergen challenge was performed on Day
14, and FEV1 was measured until 7 h post challenge. Methacholine challenge was performed on Days 1 (pre-dose),
13 (24 h pre-allergen), and 15 (24 h post-allergen), and sputum induction was performed on Days 1, 13, 14 (7 h
post-allergen), and 15.
Results: Roflumilast inhibited the allergen-induced late phase response compared to placebo; maximum % fall in FEV1
(p = 0.02) and the area under the curve (p = 0.01). Roflumilast had a more impressive effect inhibiting allergen-induced
sputum eosinophils, neutrophils, and eosinophil cationic protein (ECP) at 7 h post-allergen (all p = 0.02), and sputum
neutrophils (p = 0.04), ECP (p = 0.02), neutrophil elastase (p = 0.0001) and AHR (p = 0.004) at 24 h post-allergen.
Conclusions: This study demonstrates a protective effect of roflumilast on allergen-induced airway inflammation.
The observed attenuation of sputum eosinophils and neutrophils demonstrates the anti-inflammatory properties of
PDE4 inhibition and supports the roles of both cell types in the development of late phase bronchoconstriction
and AHR.
Trial Registration: ClinicalTrials.gov: NCT01365533
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Background
Asthma is characterized by the presence of cough, wheeze,
dyspnea, reversible airway obstruction and airway hyperre-
sponsiveness. Eosinophils are cells recognized to be a key
feature of allergic asthma [1], however patients with severe
asthma have increases in both eosinophils and neutrophils
in their sputum [2]. Furthermore, severe asthma exacerba-
tions are associated with bronchial mucosal eosinophilia
and neutrophilia, as well as upregulation of CXC chemoat-
tractants and their receptors [3]. Although current asthma
therapies such as corticosteroids are effective in inhibiting
eosinophilic inflammation through Th2 suppression, they
may enhance neutrophil accumulation into the airways and
until now therapies that effectively suppress neutrophilic
inflammation have been lacking [4,5].
The intracellular signalling molecules, cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monopho-
sphate (cGMP), are implicated in the pathophysiology of
asthma; they promote smooth muscle relaxation and
inhibit inflammation [6]. A novel approach for therapeu-
tic intervention in asthma is through regulation of the
phosphodiesterase (PDE) activity, which is the only cellu-
lar pathway available for degradation of cAMP and
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function and reduce exacerbations in chronic obstructive
pulmonary disease (COPD) [8,9] and has recently been
approved in the EU and Canada for oral once-daily treat-
ment of severe COPD.
Roflumilast is a selective inhibitor of the PDE4 isoform
which is specific for cAMP degradation, and is expressed
in several effector cells central to the pathophysiology of
asthma including eosinophils, neutrophils and lympho-
cytes [10,11]. As a significant increase in PDE4 activity has
been reported in patients with asthma or allergy compared
with healthy individuals [12,13], it is therefore of interest
to explore PDE4 inhibition as a potential therapeutic
option for treatment of atopic asthma, given the proposed
anti-inflammatory mode of action [14].
Subjects with allergic asthma develop an immediate IgE-
mediated early asthmatic response (EAR) following inhala-
tion of a sufficient dose of an allergen to which they are
sensitized [15]. Up to 50% of these subjects also develop a
late asthmatic response (LAR) beginning 3 to 4 hours after
allergen inhalation challenge [16], and an associated eleva-
tion in levels of eosinophils, basophils and mast cells,
other effector cells including T lymphocytes [17-20], and
Th2-related cytokines and chemokines [18,20-22]. Roflu-
milast is a potent and targeted PDE4 inhibitor, approved
by the European Commission as an add-on to bronchodi-
lator therapy for the treatment of severe chronic obstruc-
tive pulmonary disease (COPD) associated with chronic
bronchitis in adults with a history of frequent exacerba-
tions, and targets the underlying inflammation in COPD.
We hypothesized that roflumilast would attenuate aller-
gen-induced LAR and airway hyperresponsiveness (AHR)
through inhibition of airway inflammation. Some of the
results of this study have been previously reported in the
form of an abstract [23].
Methods
Subjects
Forty-seven non-smoking subjects with mild atopic stable
asthma underwent screening for this study. Subjects were
required to have a forced expiratory volume in one second
(FEV1 ) ≥ 70% of predicted and baseline methacholine
PC20 (the provocative concentration of methacholine caus-
ing a 20% fall in FEV1) ≤ 16 mg/mL. Subjects had no other
lung disease, no lower respiratory tract infection or wor-
sening of asthma for 6 weeks before screening, and
avoided exposure to sensitizing allergens apart from house
dust mite. Subjects were steroid-naïve and used infrequent
inhaled beta2-agonist for treatment of asthma. Beta2-ago-
nist and caffeinated beverages were withheld for at least
8 h before laboratory visits. Twenty-five subjects, 10 male/
15 female, aged 18-54 years old (Table 1) met all criteria
including the development of allergen-induced EAR and
LAR. EAR was defined by an acute fall in FEV1 ≥ 20%
within 2 h following allergen challenge, and LAR was
defined by a fall in FEV1 ≥ 15% between 3 h and 7 h
following allergen challenge.
Study Design
This trial was a two-center, double-blind, randomized, pla-
cebo-controlled, cross-over study, comparing 14 days treat-
ment with roflumilast, 500 mcg, with placebo (Figure 1).
The primary outcome was the effect of roflumilast on aller-
gen-induced airway eosinophilia. Secondary outcomes were
the allergen-induced EAR, LAR, AHR, steady-state phar-
macokinetics (PK) of roflumilast and roflumilast N-oxide,
safety and tolerability of roflumilast, and allergen-induced
airway metachromatic cells (MCC) and airway inflamma-
tory cell mediator levels. The study was registered with
http://clinicaltrials.govNCT01365533.
The study was carried out from December 2004 to
July 2005. Each site was given a block of kits containing
drug and placebo. The randomization code was compu-
ter-generated, and eligible subjects were assigned the
next available kit at the site by study staff. All subjects
and trial staff remained blinded to the random order
during the trial.
The study was approved by the ethics research board of
the respective institutions, a n ds i g n e di n f o r m e dc o n s e n t
of all subjects was obtained. Screening of subjects was
performed over 1 week and included 3 consecutive days
for assessment of responses to inhaled allergen challenge
(Figure 1). Those who developed a fall in FEV1 of ≥ 20%
within 2 h post allergen (EAR), and ≥ 15% between 3 and
7 h post allergen (LAR) were randomized to two treat-
ment periods separated by 3-5 weeks. To enter a treat-
ment period, methacholine PC20 was required to be
within one doubling dose of that measured during
screening, and FEV1 ≥ 70% of predicted. Methacholine
challenge and sputum induction were performed in the
morning of Day 1 (before dosing), Day 13 (24 h pre aller-
gen challenge), and Day 15 (24 h post allergen challenge).
Allergen challenge was performed on the morning of Day
14, and sputum was induced 7 h post allergen challenge.
Table 1 Mean subject demographics and baseline
characteristics (range)
Parameter Intent to treat population
N=2 5
Age, years 28.7 (18 - 54)
Gender, males/females 10/15
History of asthma, years 15.3 (0 - 43)
FEV1 % predicted 92.8 (75.9 - 117.1)
Methacholine PC20, mg/ml 4.0 (0.3 - 14.4)
Smokers none
Legend: FEV1: forced expiratory volume in 1 second; PC20: provocative
concentration causing a 20% fall in FEV1.
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Day 14.
Laboratory Procedures
Study Medication
Patients received one roflumilast 500 mcg or placebo
tablet orally each morning after breakfast (taken with at
least 200 mL of fluid) for 14 consecutive days. The first
dose of study drug was administered in the laboratory
after all study procedures were completed. Subjects self-
administered the study drug from Day 2 to Day 12.
Doses on Days 13 and 14 were administered in the
laboratory approximately 15 minutes before study proce-
dures. Roflumilast 500 mcg was selected because it is
well tolerated and effective in asthma control at this dose
[24].
Methacholine Inhalation Challenge
Methacholine PC20 was measured as described by Cock-
croft [25] using tidal breathing from a Wright nebulizer.
The test was terminated when a fall in FEV1 of at least
20% of the baseline value occurred.
Allergen Inhalation Challenge
FEV1 was required to be within 10% of baseline to pro-
ceed with the challenge. Allergen inhalation was per-
formed as described by O’Byrne and colleagues [16]
using the concentration of allergen extract determined
from a formula described by Cockcroft and coworkers
[26]. During the screening period, doubling concentra-
tions of allergen were administered until a ≥ 20% fall in
FEV1 at 10 minutes post allergen was reached. FEV1 was
then measured at regular intervals until 7 h after allergen
inhalation. Only subjects developing a LAR of ≥ 15% fall
in FEV1 during the screening period were eligible to par-
ticipate in the study. All subjects inhaled the same dose
of allergen for each of the two treatment periods. EAR
was defined as the largest fall in FEV1 within 2 h after
allergen challenge, and LAR was defined as the largest
fall in FEV1 between 3 h and 7 h after allergen challenge.
The early and late responses area under the curve (AUC)
were calculated from 0-2 h and 3-7 h, respectively (AUC
0-2h, AUC 3-7h) by plotting the response using graphics
software that calculated the area of the FEV1-time
response and expressed as liters by hours (Lxh).
Sputum Analysis
Sputum was induced and processed using the method
described by Pizzichini and co-workers [27]. The total cell
count was determined using a Neubauer hemocytometer
chamber (Hausser Scientific, Blue Bell, PA) and expressed
as the number of cells per gram of sputum. Cells were pre-
pared on 4 glass slides. Two slides were stained with Diff
Quik (American Scientific Products, McGaw Park, IL) and
duplicate differential counts (400 cells/slide) were aver-
aged. Two slides were fixed in Carnoy’ss o l u t i o n( 6 0 %
ethanol, 30% chloroform and 10% glacial acetic acid),
stained with toluidine blue (Sigma-Aldrich, St. Louis,.
MO) which stains the nuclei of all cells pale blue, and gly-
cosaminoglycan-containing granules in the cytoplasm of
mast cells and basophils stain metachromatically red/
Figure 1 Study schematic and subject disposition. D: day; PLA: placebo; ROF: roflumilast.
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assessed for positive metachromatic staining, and
expressed as the number of metachromatic cells per gram
of sputum. Supernatant was stored at -70°C and assayed in
duplicate using commercial ELISAs for interleukin (IL)-8,
myeloperoxidase and neutrophil elastase (R&D Systems,
Minneapolis, MN). Eosinophil cationic protein was mea-
sured using UniCap (Somagen Diagnostics, Edmonton,
AB).
Pharmacokinetic Assessments
Blood was collected from 15 subjects at one trial site for
pharmacokinetic assessments on Day 14 of each treatment
period. Blood was collected pre-dose and post-dose at
15 min, 30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 6 h, 8 h,
12 h, and 24 h. Venous blood was withdrawn into vacuum
blood collection tubes containing lithium heparin, and
plasma was separated within 30 min by centrifugation at
1000 g for 10 min in a refrigerated centrifuge. Plasma sam-
ples were frozen at -20°C then assayed for roflumilast and
roflumilast-N-oxide. Analytical measurements of roflumi-
last and roflumilast N-oxide were performed by a validated
method using high performance liquid chromatography
(HPLC) coupled with tandem mass spectrometry (HPLC-
MS/MS) and allowed an LLOQ of 0.1 μg/L for both, roflu-
milast, and roflumilast N-oxide using 0.4 mL human
plasma.
Statistical Analysis
The per-protocol data were analyzed to accommodate the
crossover design, thereby removing data from subjects not
completing both study periods. Data are presented from
22 subjects as mean ± standard error of the mean (SEM)
unless otherwise noted. Methacholine PC20, sputum cell
numbers and mediator levels were log-transformed prior
to analyses. An ANCOVA adopted for the crossover
design was performed to evaluate the effects of treatment
and period; fixed factors were age, gender, value at the end
of washout, and center. The random factor patient nested
in sequence was included in the model. It was assumed
that the random errors were independent and identically
distributed with mean zero and equal variance.
Results
Two subjects withdrew prematurely from the study due to
adverse events (depression, asthma), and one subject was
excluded for using inhaled corticosteroids during the trial.
Statistical analyses were carried out on the 22 subjects
who completed the study per protocol. Baseline character-
istics are shown in Table 1.
Sputum Inflammatory Cells
Roflumilast treatment had a significant effect on the total
leukocyte count in sputum, thus cell populations are
shown as absolute numbers rather than percentages.
After allergen inhalation, with placebo treatment, sputum
eosinophils increased from a pre-allergen baseline of
28 ± 6/g to 744 ± 199/g at 7 h and 850 ± 227/g at 24 h
post-allergen (both p < 0.0001). Compared with placebo,
roflumilast inhibited the allergen-induced increase in
sputum eosinophils from a pre-allergen value of 29 ± 12/
g to 530 ± 182/g at 7 h (p = 0.015) and 446 ± 120/g (p =
0.051) at 24 h post-allergen (Figure 2).
With placebo treatment, after allergen inhalation, spu-
tum neutrophils increased from a pre-allergen baseline of
1.15 ± 0.34 × 10
3/g to 4.13 ± 0.1.26 × 10
3/g and 4.56 ±
0.1.39 × 10
3/g at 7 and 24 h post-allergen (both p <
0.0001). Compared with placebo, roflumilast inhibited the
allergen-induced increase in sputum neutrophils from
1.13 ± 0.33 × 10
3/g pre-allergen to 1.66 ± 0.32 × 10
3/g at
7ha n d1 . 6 1±0 . 3 8×1 0
3/g at 24 h post-allergen (p =
0.017 and p = 0.04, respectively) (Figure 2).
With placebo, allergen inhalation increased sputum
MCC (basophils and mast cells) from a pre-allergen base-
line of 1.0 ± 1.0/g before challenge, to 10 ± 4.0/g (p <
0.0001) at 7 h, and 8.0 ± 3.0/g (p = 0.002) at 24 h post-
allergen. Compared with placebo, roflumilast inhibited the
allergen-induced increase in sputum MCC from pre-aller-
gen value of 1.0 ± 1.0/g before to 3.0 ± 1.0/g and 4.0 ±
2.0/g at 7 and 24 h post-allergen (p = 0.003 and 0.37,
respectively) (Figure 2).
After 13 days of dosing, subjects receiving roflumilast
had no change in baseline numbers of sputum eosino-
phils, neutrophils, or MCC (basophils and mast cells)
(Figure 2).
Sputum Fluid Phase Mediators
The sputum supernatant was assayed for mediators
associated with the activation and degranulation of eosi-
nophils and neutrophils. With placebo treatment, the
pre-allergen level of ECP rose significantly from 50.4 ±
13.8 mcg/mL to 283.2 ± 62.0 mcg/mL and 304.5 ± 58.5
mcg/mL at 7 h and 24 h post-allergen (p < 0.001). After
roflumilast, this increase was attenuated from pre-aller-
gen value of 45.5 ± 15.0 mcg/mL to 178.2 ± 57.6 mcg/
mL and 219.9 ± 72.5 mcg/mL at 7 h and 24 h post-
allergen, respectively (both p < 0.02). The moderate
increase in neutrophil elastase from 21.9 ± 10.2 mcg/mL
pre-allergen to 43.0 ± 13.9 mcg/mL at 24 h post-aller-
gen following placebo treatment was significantly atte-
nuated by roflumilast, from 20.6 ± 9.8 mcg/mL pre-
a l l e r g e nt o2 1 . 5±8 . 6m c g / m La t2 4hp o s t - a l l e r g e n
(p = 0.0001). Post-allergen levels of myeloperoxidase
and IL-8 were consistently lower with roflumilast treat-
ment, however not statistically different than placebo
(p > 0.05) (Figure 3).
After 13 days of dosing, subjects receiving roflumilast
had no change in the level of ECP, IL-8, myeloperoxi-
date or neutrophil elastase (Figure 3).
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There was no difference in the baseline FEV1 after 14 days
of treatment with roflumilast or placebo (3.50 ± 0.18 L vs
3.54 ± 0.17 L, respectively, p = 0.28. Both allergen-induced
early and late falls in FEV1 were significantly inhibited by
roflumilast (early AUC 0-2 h -0.78 ± 0.10 Lxh compared
to placebo -0.94 ± 0.12 Lxh, (p = 0.047) and late AUC 3-7
h -1.19 ± 0.25 Lxh compared to placebo -1.73 ± 0.29 Lxh,
Figure 2 Mean sputum inflammatory cells (± SEM) at baseline before treatment with roflumilast (solid bars) or placebo (open bars),
after 13 days’ treatment, and 7 h and 24 h after allergen challenge. Roflumilast significantly inhibited the allergen-induced influx of sputum
eosinophils, neutrophils and metachromatic cells (p < 0.05).
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early response was -0.87 ± 0.08 L (23.4% fall from base-
line) with roflumilast compared to -0.93 ± 0.10 L (26.2%
fall from baseline) with placebo (p = 0.12). The maximum
change in FEV1 during the late response was -0.57 ± 0.09
L (16.2% fall from baseline) with roflumilast compared to
-0.73 ± 0.10 L (20.7% fall from baseline) with placebo (p =
0.02) (Figure 4).
Figure 3 Mean sputum fluid phase mediators (± SEM) at baseline before treatment with roflumilast (solid bars) or placebo (open
bars), after 13 days’ treatment, and 7 h and 24 h after allergen challenge. Roflumilast significantly inhibited the allergen-induced increased
level of eosinophil cationic protein (ECP) and neutrophil elastase (NE) (p < 0.05).
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T h em e t h a c h o l i n eP C 20 was unchanged following 13
days’ treatment with placebo or roflumilast (p > 0.05),
and fell significantly 24 h post-allergen with both pla-
cebo and roflumilast (p = 0.022 and < 0.0001, respec-
tively). However, roflumilast significantly attenuated
the allergen-induced fall in AHR from 5.64 ± 1.26 mg/
mL pre-allergen to 3.65 ± 0.81 mg/mL 24 h post-aller-
gen, compared to placebo from 5.39 ± 1.18 mg/mL
pre-allergen to 1.80 ± 0.42 mg/mL 24 h post-allergen
(p = 0.004).
Safety
One subject under treatment with roflumilast experi-
enced a serious adverse event of depression and was
withdrawn from the study. This subject did not have a
history of depression. Headache was the most fre-
quently reported adverse event (AE) with roflumilast
treatment (4 roflumilast versus 0 placebo), followed by
nausea (2 roflumilast versus 0 placebo). The majority
of AEs were not considered related to study medica-
tion. There were no significant differences between
treatments in median values of hematology and blood
chemistry variables.
Pharmacokinetics in Plasma
Pharmacokinetic profiles were obtained from 15 subjects
at Day 14. Following repeated oral doses of roflumilast,
estimates of roflumilast and the active metabolite
N-oxide roflumilast at Day 14 show maximum plasma
concentrations of 7.04 ± 0.65 mcg/L and 26.8 ± 2.59
mcg/L reached at 1.83 ± 0.27 h and 4.37 ± 0.5 h, respec-
tively (Figure 5). The pharmacokinetic profiles and esti-
mates of roflumilast and roflumilast N-oxide are similar
to those in previous pharmacokinetic studies in healthy
volunteers [28].
Discussion
The orally active PDE4 inhibitors roflumilast and
CDP840, given either as a single dose or regularly are
known to inhibit the allergen-induced LAR and AHR
[29-31], and rolfumilast has been shown to reduce spu-
tum eosinophil and neutrophils in subjects with COPD
[32]. We hypothesized that oral roflumilast would also
attenuate allergen-induced airway inflammation, includ-
ing neutrophilia, which is not generally a target for
asthma treatment asthma [3]. This study examined the
safety of 14 days’ oral treatment with roflumilast 500 mcg
Figure 4 Mean percent fall in FEV1 (± SEM) during the early and late asthmatic responses. Roflumilast significantly inhibited the area of
the early and late responses (p < 0.05). FEV1: forced expiratory volume in 1 second.
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induced airway inflammation. The results show that
roflumilast attenuated allergen-induced accumulation of
inflammatory cells and inflammatory mediators.
In asthma, there is an increase in the number of
inflammatory cells within the airways. It is believed that
through the release of their mediators and enzymes [4-6]
these effector cells contribute to the persistence of
inflammation, AHR and increased bronchial tone [1-3].
Roflumilast is a selective PDE4 inhibitor, this inhibition
leads to increased cAMP levels in inflammatory cells,
rendering them less likely to respond to stimuli. Thus,
cell functions, including chemotaxis, survival and activa-
tion, which are mediated through cAMP, will be impaired
with roflumilast treatment. Roflumilast has been shown
to block inflammatory cell influx through inhibition of P-
and E-selectin expression on endothelial cells, and
CD11b expression on neutrophils [33], and blocks the
release of various inflammatory mediators including
TNF-alpha, LTB4, IL-4 and IL-5 [34]. In keeping with the
proposed broad anti-inflammatory effects of roflumilast,
the allergen-induced increase in eosinophils, neutrophils,
MCC and total leukocyte counts in sputum were inhib-
ited with active treatment. This inhibitory effect on
inflammatory cell numbers was also observed in the
sputum of subjects with COPD where 500 mcg roflumi-
last once daily for 4 weeks decreased the total cell count
[32].
We hypothesized that roflumilast would suppress the
migration and activation of cells involved in the allergic
immune response in the airways following allergen inha-
lation challenge, and thus reduce the physiological
responses of EAR, LAR and AHR. This study demon-
strates that roflumilast attenuates allergen-induced phy-
siologic responses in subjects with mild allergic asthma,
albeit the effect is small as compared to inhaled corticos-
teroids [35]. Inhibition of physiologic responses is coinci-
dent with a larger inhibition of airway inflammation,
especially the neutrophil population. Airway neutrophilia
has been shown to be elevated in severe asthma, however
this could be due, in part, to inhaled corticosteroid treat-
ment [36]. As such, the role of the neutrophil in asthma
is still uncertain. Mast cells and basophils are positioned
to play a major role in the development of the EAR fol-
lowing IgE-dependent release of histamine and cysteinyl
leukotrienes. Inhibition of activation of MCC in sputum
by inhaled allergen provides one mechanism for inhibi-
tion of the EAR by roflumilast. Likewise, reduced accu-
mulation of eosinophils, neutrophils and their mediators
in the airways post allergen reduces inflammatory signals
Figure 5 Mean plasma concentration (± SEM) of roflumilast and the active metabolite roflumilast N-oxide at Day 14.
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allergen-induced EAR and LAR and AHR is unlikely to
be mediated through smooth muscle relaxation because
we did not observe improvements in FEV1 post-dosing
consistent with the lack of direct bronchodilatory activity
[37].
Conclusions
This is the first study to demonstrate inhibition of both
allergen-induced airway eosinophilia and neutrophilia with
pharmacological intervention, and suggests that the broad
anti-inflammatory properties of roflumilast may be effec-
tive in attenuating the airway neutrophilic inflammation,
which is not well-controlled by corticosteroids.
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